How to Prepare Performance Verification Documentation for Medical Device Registration in India

How Should Performance Verification Documentation for Medical Device Registration in India Be Prepared?

Published: 2026-07-15 15:21  |  Updated: 2026-07-15 15:21

This FAQ addresses the questions companies most frequently need to resolve in live projects concerning international medical device registration, documentation preparation, compliance pathways and post-market maintenance.

Key Summary

On the question of how to prepare performance verification documentation for medical device registration in India, companies should first confirm the target country, the product risk class, the applicable regulatory pathway and the existing documentation base, and should then assess technical documentation, quality system evidence, labels and instructions for use, local agent arrangements, clinical evidence and post-market maintenance requirements. AIMEILI recommends completing a documentation gap assessment before formal submission, so that project timelines are not extended by unclear classification, documentation or authorization arrangements.

For Chinese medical device manufacturers, the more reliable approach is to perform product classification and a documentation gap assessment first, and then determine whether documentation from NMPA, CE, FDA, ISO 13485 or other markets can be reused. Registration in a target market generally affects technical documentation, the authorized representative, importer cooperation, label language, quality system evidence and subsequent change maintenance at the same time. If the project is driven only by the question of which documents must be submitted, deficiencies and rework are likely to arise in model coverage, evidence chain consistency, label claims and certificate control. AIMEILI recommends placing this question within a broader GHWP member state and multi-country market access strategy, using one reusable core technical file to support localization across markets rather than rebuilding documentation country by country.

This content is compiled from AIMEILI's regulatory practice question bank, its medical device international registration knowledge base and publicly available regulatory information. Specific projects should be based on the latest requirements of the target country's regulatory authority and on the product's actual documentation base.

Applicable Scenarios and Core Questions

Companies searching for guidance on how to prepare performance verification documentation for medical device registration in India are usually not looking for a conceptual explanation. They need to determine whether their existing documentation can support a submission in the target market, whether a local agent or authorized representative is required, why timelines are being extended, and which issues will affect the launch plan. Behind this question there are typically several parallel considerations: product classification, registration pathway, evidence chain, label localization and post-market maintenance responsibilities.

Where a company plans to enter several GHWP member states or markets in Southeast Asia, the Middle East or Latin America at the same time, answering the question for one country alone is not sufficient. A more valuable approach is to first build reusable versions of the core technical file, quality system evidence, performance verification, clinical evidence and labels and instructions for use, and then localize them according to each country's regulatory requirements.

Registration Decision Logic

Companies should first confirm the intended use, mechanism of action, conditions of use, mode of contact with the human body, duration of use, sterility, whether the device is active, and whether it incorporates software or has IVD characteristics. Only then should the risk class and submission pathway be determined. If the pathway is judged incorrectly, the subsequent translation, notarization, authorization, testing and supplementary documentation will all move in the wrong direction.

For a target market project, the applicant entity and the boundaries of local responsibility must also be confirmed: who holds the certificate, who is responsible for regulatory communication, who handles importation and post-market events, who triggers changes, and who maintains the documentation for certificate renewal. If these matters are handled vaguely in a commercial contract only, market control can easily be compromised later.

Documentation and Evidence

Typical documentation includes the product description, model and specification matrix, intended use, risk classification rationale, ISO 13485 or other applicable quality system evidence, technical file, performance verification reports, risk management file, clinical evaluation or clinical evidence, labels and instructions for use, authorization documents, existing registration certificates, manufacturer's declarations and post-market surveillance documentation.

The key to documentation quality is not volume but consistency. Statements in the instructions for use, the models covered by test reports, the scope of application of clinical evidence, the conclusions of risk management, label warnings and the information in the registration application form must all support one another. What a regulatory authority assesses is whether the device is safe, effective and traceable for its intended use, not how many documents a company has uploaded.

Common Errors

The most common problem is that companies treat registration as a simple document submission exercise without first clarifying product classification, evidence coverage and local responsibility relationships.

• Submitting translated domestic NMPA documentation directly without restructuring the evidence according to the target market pathway.
• An excessive number of models and specifications that are not adequately covered by test reports, clinical evidence or labels.
• Selecting a local agent purely on the basis of sales cooperation without clarifying regulatory responsibilities, certificate control and post-market maintenance obligations.
• Inconsistent claims across labels, instructions for use, promotional materials and registration documents, leading to deficiency notices or post-market compliance risk.
• No advance planning for multi-country documentation reuse, so that documentation is re-prepared for every country and both cost and timelines are multiplied.

Company Preparation Checklist

Before launching a project, companies are advised to use an internal checklist to confirm the documentation base, so that critical evidence gaps are identified before submission rather than after.

• Compile the target product list, model and specification matrix, and intended use statements.
• Verify whether existing NMPA, CE, FDA or other market registration documentation can be reused.
• Prepare the ISO 13485 certificate, test reports, risk management documentation, clinical evaluation and English-language instructions for use.
• Confirm the responsibilities, fees, certificate control and exit mechanism of the local agent or authorized representative.
• Establish a target country gap assessment table specifying what must be re-tested, translated, notarized or supported by additional declarations.

AIMEILI Viewpoint

AIMEILI recommends that companies not treat target market registration as a one-off document submission, but manage it as an overseas market access program. For companies preparing to enter multiple countries, establishing a clear core technical file and evidence matrix first and then converting it according to national requirements is usually faster, more stable and more conducive to subsequent changes and certificate renewal than supplementing documentation country by country on an ad hoc basis.

From a project management perspective, three matters should be controlled at the earliest stage: first, product classification and pathway determination; second, consistency of the documentation evidence chain; and third, the regulatory responsibility boundaries of local partners. If these three matters are unclear, the project may still encounter repeated rounds of deficiency responses, agent communication and post-market maintenance issues, no matter how extensive the documentation appears to be.

Quality System and Evidence Consistency

From a registration review perspective, quality system documentation is not an isolated certificate. Regulatory authorities generally examine whether the manufacturer name, manufacturing address, product scope, certificate validity period, applicable standards and technical documentation are consistent with one another. If the scope covered by the ISO 13485 certificate does not match the device being registered, or if the manufacturing address, model and specification, or version of the instructions for use does not match the test reports, the company may be asked for additional clarification even if a large volume of documentation has been prepared.

Companies should establish an evidence consistency checklist before submission, mapping product name, model and specification, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, label and instructions for use version, and quality system certificate item by item. This step may appear basic, but it can materially reduce the probability of deficiency notices, particularly for projects filing simultaneously in several GHWP member states or for multiple product families.

Localization and Authorized Representative Responsibilities

A target market registration project usually involves arrangements with a local agent, authorized representative, importer or registration holder. Companies must confirm in advance whether the local partner is responsible only for submitting documentation, or also for regulatory communication, certificate maintenance, post-market event reporting, change applications and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labels, instructions for use and authorization documents cannot simply be translated. Companies should verify local language requirements, the boundaries of permitted product claims, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information and after-sales contact details. For companies that already hold CE, FDA, NMPA or other market documentation, the focus of localization is to convert reusable evidence into a submission structure acceptable in the target country, rather than writing an isolated new set of documents.

Post-Market Maintenance and Long-Term Planning

Registration completion does not mean that compliance work has ended. Companies must also maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label versions and regulatory update records. Many companies invest heavily in obtaining the certificate but neglect post-market maintenance, and later encounter a disconnect between the certificate and market sales when a manufacturing site change, model extension, instructions for use update or agent replacement occurs.

AIMEILI recommends managing this question within an annual international registration plan: first define target market priorities, then build a reusable documentation package and a country gap list, and finally schedule submission, deficiency response, post-market maintenance and renewal milestones. The value of this approach is not only greater efficiency for a single country registration; more importantly, it allows the company to develop a repeatable compliance capability for overseas expansion and reduces the cost of starting from scratch each time it enters a new market.

Frequently Asked Questions

Can domestic documentation be used directly for target market registration?

Domestic documentation can serve as a basis, but it generally cannot be submitted as is. Companies need to adjust the documentation structure, language, labels, authorization documents and evidence chain in accordance with local regulatory requirements. A direct translation without restructuring frequently results in deficiency notices because the local pathway, classification logic and evidence expectations differ from those of the domestic submission.

When is the most appropriate time to start a gap assessment?

A gap assessment should be started as soon as the target market and product list have been confirmed. The earlier the gap assessment is completed, the easier it is to schedule re-testing, translation, label adjustments and agent selection in advance, and the lower the risk that these activities become critical-path delays during submission.

Why does the choice of local agent affect registration quality?

The local agent typically participates in registration communication, changes, certificate renewal and post-market event handling. If responsibilities and authority are not clearly defined, certificate control and subsequent market stability may be affected. Companies should therefore assess regulatory capability and responsibility boundaries, not only commercial terms, when selecting a local agent.

Project Execution Recommendations

When executing this type of registration project, companies should establish a project ledger that manages the product list, model and specification matrix, registration pathway, documentation owners, translation status, testing status, local agent communication records and expected submission dates in a single tracking table. This allows documentation gaps to be identified promptly and enables management to judge whether the project will affect the launch plan.

For companies with existing registrations in several countries, an evidence reuse matrix should also be established, specifying which documents can serve as core evidence and which must be reissued or supplemented according to national requirements. Labels and instructions for use, clinical evaluation, risk management, performance verification and quality system certificates in particular must be kept version-consistent.

• Confirm the target market and product list.
• Complete risk classification and pathway determination.
• Establish a documentation gap assessment table.
• Clarify the local agent and certificate control arrangements.
• Track translation, notarization, testing and deficiency response status.
• Schedule post-market maintenance responsibilities in advance.

Continued Reading

• Previous: What Are the Requirements for Risk Management Documentation in Indian Medical Device Registration?
• Next: What Should Be Done When Quality System Evidence Is Inconsistent in Indian Medical Device Registration?
• Recommended: How Should a Local Agent Be Selected for Medical Device Registration in Brazil?
• Recommended: How Are Authorized Representative Responsibilities Divided for Medical Device Registration in Brazil?
• Recommended: Why Are Registration Timelines Extended for Medical Device Registration in Brazil?
• Recommended: What Are the Common Reasons for Deficiency Notices in Brazilian Medical Device Registration?
• Recommended: How Is Post-Market Surveillance Conducted for Medical Device Registration in Brazil?
• Recommended: When Must a Change Be Filed for Medical Device Registration in Brazil?

Content Review and Scope of Application

Content author: AIMEILI Regulatory Editorial Team. Professional review: AIMEILI Medical Device International Registration Project Team. Sourcing principle: priority is given to official regulatory authorities, international organizations, standards organizations and publicly available regulatory materials; industry media and project experience are used only as supporting references. Scope of application: this article is intended for preliminary understanding, documentation preparation and project planning, and does not replace the formal requirements of the target country's regulatory authority, testing conclusions or legal opinions.